Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI 48202, USA.
Hypertension. 2013 Jul;62(1):99-104. doi: 10.1161/HYPERTENSIONAHA.113.01164. Epub 2013 May 6.
Tubuloglomerular feedback (TGF) is a mechanism that senses NaCl in the macula densa (MD) and causes constriction of the afferent arteriole. CO, either endogenous or exogenous, inhibits TGF at least in part via cGMP. We hypothesize that CO in the MD, acting via both cGMP-dependent and -independent mechanisms, attenuates TGF by acting downstream from depolarization and calcium entry into the MD cells. In vitro, microdissected rabbit afferent arterioles and their MD were simultaneously perfused and TGF was measured as the decrease in afferent arteriole diameter. MD depolarization was induced with ionophores, while adding the CO-releasing molecule-3 to the MD perfusate at nontoxic concentrations. CO-releasing molecule-3 blunted depolarization-induced TGF at 50 μmol/L, from 3.6±0.4 to 2.5±0.4 µm (P<0.01), and abolished it at 100 μmol/L, to 0.1±0.1 μm (P<0.001; n=6). When cGMP generation was blocked by guanylyl cyclase inhibitor LY83583 added to the MD, CO-releasing molecule-3 no longer affected depolarization-induced TGF at 50 μmol/L (2.9±0.4 versus 3.0±0.4 µm) but partially inhibited TGF at 100 μmol/L (to 1.3±0.2 μm; P<0.05; n=9). Experiments using eicosatetraynoic acid and indomethacin suggest arachidonic acid metabolites do not mediate the cGMP-independent effect of CO. We then added the calcium ionophore A23187 to the MD, which caused TGF (4.1±0.6 μmol/L); A23187-induced TGF was inhibited by CO-releasing molecule-3 at 50 μmol/L (1.9±0.6 μmol/L; P<0.01) and 100 μmol/L (0.2±0.5 μmol/L; P<0.001; n=6). We conclude that CO inhibits TGF acting downstream from depolarization and calcium entry, acting via cGMP at low concentrations, but additional mechanisms of action may be involved at higher concentrations.
管球反馈(TGF)是一种感知致密斑(MD)中 NaCl 的机制,导致入球小动脉收缩。CO,无论是内源性还是外源性的,至少部分通过 cGMP 抑制 TGF。我们假设 MD 中的 CO 通过 cGMP 依赖和非依赖机制发挥作用,通过作用于 MD 细胞去极化和钙内流的下游来减弱 TGF。在体外,同时灌流微分离的兔入球小动脉及其 MD,并测量入球小动脉直径的减小作为 TGF。用离子载体诱导 MD 去极化,同时在非毒性浓度下将 CO 释放分子-3 添加到 MD 灌流液中。CO 释放分子-3 在 50 μmol/L 时使离子载体诱导的 TGF 减弱,从 3.6±0.4 降至 2.5±0.4 µm(P<0.01),在 100 μmol/L 时完全消除,降至 0.1±0.1 µm(P<0.001;n=6)。当 MD 中加入鸟苷酸环化酶抑制剂 LY83583 阻断 cGMP 生成时,CO 释放分子-3 不再影响 50 μmol/L 时离子载体诱导的 TGF(2.9±0.4 与 3.0±0.4 µm),但部分抑制 100 μmol/L 时的 TGF(至 1.3±0.2 µm;P<0.05;n=9)。使用二十碳四烯酸和吲哚美辛的实验表明,花生四烯酸代谢物不介导 CO 的 cGMP 非依赖性作用。然后,我们向 MD 中加入钙离子载体 A23187,导致 TGF(4.1±0.6 μmol/L);CO 释放分子-3 在 50 μmol/L(1.9±0.6 μmol/L;P<0.01)和 100 μmol/L(0.2±0.5 μmol/L;P<0.001;n=6)时抑制 A23187 诱导的 TGF。我们得出结论,CO 通过 cGMP 在低浓度下作用于去极化和钙内流的下游抑制 TGF,但在较高浓度下可能涉及其他作用机制。